Article

AMO pledges $1 million to support research in refractive lenticular science

Advanced Medical Optics (AMO) announced it will pledge $1 million to support independent research/programming in refractive lenticular science sponsored by the American Society of Cataract and Refractive Surgery (ASCRS) Foundation. I. Howard Fine, MD, ASCRS foundation chairman, announced the AMO grant during the opening general session Saturday morning.

Advanced Medical Optics (AMO) announced it will pledge $1 million to support independent research/programming in refractive lenticular science sponsored by the American Society of Cataract and Refractive Surgery (ASCRS) Foundation. I. Howard Fine, MD, ASCRS foundation chairman, announced the AMO grant during the opening general session Saturday morning.

"In 2006, we will begin work on a substantial multi-year program to support new research and new educational programs that explore the rapidly emerging science of refractive lenticular surgery," Dr. Fine said. "In the coming years, the ever-increasing merger of cataract and laser refractive science will change our practices and greatly increase what we can offer our patients."

AMO President and Chief Executive Officer James V. Mazzo commended the ASCRS Foundation for its foresight and leadership in forming this effort to advance refractive corneal and lenticular research and education.

"We hope that other industry participants will join AMO and offer their resources and support to the ASCRS Foundation to ensure the program's sustained success," Mazzo said.

The ASCRS Foundation - supported by unrestricted donations from ASCRS members and the ophthalmic industry - funds ophthalmic research, public education, and charitable activities in the developing world.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.